Gilead HIV Drug Gets FDA OK

8/10/11

Gilead Sciences (NASDAQ: GILD), the world’s largest maker of HIV drugs, said today that the FDA has approved a new once-daily pill the company has developed for patients with HIV. The drug is a combination of three antivirals—emtricitabine/rilpivirine/tenofovir disoproxil fumarate—that will be marketed under the name Complera. This is the second once-daily HIV pill from Foster City, CA-based Gilead, following a combination of efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), which Gilead markets in partnership with Bristol-Myers Squibb.

By posting a comment, you agree to our terms and conditions.